                         SEQUENCE LISTING

<110>  The Regents of the University of California
       Sun, Ren
       Young, Arthur P.
       Ching Hai Wu, Nicholas
 
<120>  VACCINES AND USES THEREOF

<130>  034044130WO1

<150>  US 61/976,024
<151>  2014-04-07

<150>  US 62/073,717
<151>  2014-10-31

<150>  US 62/073,777
<151>  2014-10-31

<150>  US 62/127,775
<151>  2015-03-03

<160>  149   

<170>  PatentIn version 3.5

<210>  1
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  1

Ala Tyr Met Leu Glu Arg Glu Leu Val Arg Lys 
1               5                   10      


<210>  2
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  2

Ile Leu Thr Asp Ser Gln Thr Ala Thr Lys 
1               5                   10  


<210>  3
<211>  24
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  3

Asn Leu Ala Lys Gly Glu Lys Ala Asn Val Leu Ile Gly Gln Gly Asp 
1               5                   10                  15      


Val Val Leu Val Met Lys Arg Lys 
            20                  


<210>  4
<211>  24
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  4

Asn Leu Ala Lys Gly Glu Lys Ala Asn Val Leu Ile Gly Gln Gly Asp 
1               5                   10                  15      


Ile Val Leu Val Met Lys Arg Lys 
            20                  


<210>  5
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  5

Tyr Ser His Gly Thr Gly Thr Gly Tyr Thr 
1               5                   10  


<210>  6
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  6

Tyr Ser His Trp Thr Gly Thr Gly Tyr Thr 
1               5                   10  


<210>  7
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  7

Arg Gly Lys Leu Lys Arg Arg Ala Ile Ala Thr Pro Gly Met Gln 
1               5                   10                  15  


<210>  8
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  8

Arg Gly Lys Leu Lys Arg Arg Ala Ile Ala Thr Pro Trp Met Gln 
1               5                   10                  15  


<210>  9
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  9

Gly Leu Gln Ser Ser Asp Asp Phe Ala Leu Ile 
1               5                   10      


<210>  10
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  10

Lys Leu Leu Gly Ile Asn Met Ser Lys 
1               5                   


<210>  11
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  11

Lys Leu Val Gly Ile Asn Met Ser Lys 
1               5                   


<210>  12
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  12

Asn Arg Thr Gly Thr Phe Glu Phe 
1               5               


<210>  13
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  13

Asn Lys Thr Gly Thr Phe Glu Phe 
1               5               


<210>  14
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  14

Asn Glu Ser Ala Asp Met Ser Ile Gly Val Thr Val Ile 
1               5                   10              


<210>  15
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  15

Asn Glu Ser Ala Asp Met Gly Ile Gly Val Thr Val Ile 
1               5                   10              


<210>  16
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  16

Leu Gly Pro Ala Thr Ala Gln Met Ala Leu Gln Leu Phe Ile Lys 
1               5                   10                  15  


<210>  17
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  17

Leu Cys Pro Ala Thr Ala Gln Met Ala Leu Gln Leu Phe Ile Lys 
1               5                   10                  15  


<210>  18
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  18

Asn Glu Lys Lys Ala Lys Leu Ala Asn 
1               5                   


<210>  19
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  19

Ser Pro Gly Met Met Met Gly Met Phe Asn 
1               5                   10  


<210>  20
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  20

Ser Pro Gly Val Met Met Gly Met Phe Asn 
1               5                   10  


<210>  21
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  21

Glu Met Ala Thr Lys Ala Asp Tyr 
1               5               


<210>  22
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  22

Glu Met Ala Thr Thr Ala Asp Tyr 
1               5               


<210>  23
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  23

Tyr His Ala Asn Asn Ser Thr Asp Thr Val Asp Thr Ile Leu Glu Lys 
1               5                   10                  15      


Asn Val 
        


<210>  24
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  24

Tyr His Ser Asn Asn Ser Thr Asp Thr Val Asp Thr Ile Leu Glu Lys 
1               5                   10                  15      


Asn Val 
        


<210>  25
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  25

Tyr His Ala Asn Asn Ser Thr Asp Thr Val Asp Thr Ile Leu Glu Gln 
1               5                   10                  15      


Asn Val 
        


<210>  26
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  26

Arg Gly Ile Asn Asp Arg Asn Phe Trp 
1               5                   


<210>  27
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  27

Arg Trp Ile Asn Asp Arg Asn Phe Trp 
1               5                   


<210>  28
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  28

Glu Leu Arg Ser Arg Tyr Trp Ala 
1               5               


<210>  29
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  29

Glu Leu Arg Ser Arg His Trp Ala 
1               5               


<210>  30
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  30

Ser Phe Gln Gly Arg Gly Val Phe Glu Leu 
1               5                   10  


<210>  31
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  31

Ser Phe Gln Gly Arg Gly Val Phe Glu Phe 
1               5                   10  


<210>  32
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  32

Leu Ser Thr Arg Gly Val Gln Ile 
1               5               


<210>  33
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  33

Trp His Ser Asn Leu Asn Asp Ala Thr Tyr Gln Arg Thr Arg Ala Leu 
1               5                   10                  15      


Val 
    


<210>  34
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  34

Trp His Ser Asn Leu Asn Asp Ser Thr Tyr Gln Arg Thr Arg Ala Leu 
1               5                   10                  15      


Val 
    


<210>  35
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  35

Trp His Ser Asn Leu Asn Asp Ala Thr Tyr Gln Arg Thr Arg Ser Leu 
1               5                   10                  15      


Val 
    


<210>  36
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  36

Trp His Ser Asn Leu Asn Asp Thr Thr Tyr Gln Arg Thr Arg Ala Leu 
1               5                   10                  15      


Val 
    


<210>  37
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  37

Trp His Ser Asn Leu Asn Asp Thr Thr Tyr Gln Arg Thr Arg Ser Leu 
1               5                   10                  15      


Val 
    


<210>  38
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  38

Ala Tyr Glu Arg Met Cys Asn Ile Leu Lys Gly Lys Phe Gln Thr 
1               5                   10                  15  


<210>  39
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  39

Phe Val Ile Arg Glu Pro Phe Ile 
1               5               


<210>  40
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  40

Phe Ser Tyr Lys Tyr Gly Asn Gly Val Trp 
1               5                   10  


<210>  41
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  41

Phe Ser Phe Lys Tyr Gly Asn Gly Val Trp 
1               5                   10  


<210>  42
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  42

Cys Met Arg Pro Cys Phe Trp Val Glu Leu Ile 
1               5                   10      


<210>  43
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  43

Cys Ile Arg Pro Cys Phe Trp Val Glu Leu Ile 
1               5                   10      


<210>  44
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  44

Cys Met Arg Pro Phe Phe Trp Val Glu Leu Ile 
1               5                   10      


<210>  45
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  45

Gly Pro Asp Asp Gly Ala Val Ala Val Leu Lys Tyr 
1               5                   10          


<210>  46
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  46

Gly Pro Asp Asn Gly Ala Val Ala Val Leu Lys Tyr 
1               5                   10          


<210>  47
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  47

Gly Glu Ala Pro Ser Pro Tyr Asn Ser Arg Phe Glu Ser Val Ala Trp 
1               5                   10                  15      


<210>  48
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  48

Gly Lys Ala Pro Ser Pro Tyr Asn Ser Arg Phe Glu Ser Val Ala Trp 
1               5                   10                  15      


<210>  49
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  49

Gly Glu Val Pro Ser Pro Tyr Asn Ser Arg Phe Glu Ser Val Ala Trp 
1               5                   10                  15      


<210>  50
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  50

Gly Glu Ala Pro Ser Pro Tyr Asn Ser Lys Phe Glu Ser Val Ala Trp 
1               5                   10                  15      


<210>  51
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  51

Lys Asn Thr Asp Leu Glu Val Leu Met Glu Trp Leu Lys Thr Arg Pro 
1               5                   10                  15      


Ile Leu Ser Pro Leu 
            20      


<210>  52
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  52

Lys Ser Thr Asp Leu Glu Val Leu Met Glu Trp Leu Lys Thr Arg Pro 
1               5                   10                  15      


Ile Leu Ser Pro Leu 
            20      


<210>  53
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  53

Lys Asn Thr Asp Leu Glu Ala Leu Met Glu Trp Leu Lys Thr Arg Pro 
1               5                   10                  15      


Ile Leu Ser Pro Leu 
            20      


<210>  54
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  54

Gly Glu Lys Ala Asn Val Leu Ile Gly Gln Gly Asp Val Val Leu Val 
1               5                   10                  15      


Met Lys Arg Lys 
            20  


<210>  55
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  55

Tyr Ser His Gly Thr Gly Thr Gly Tyr 
1               5                   


<210>  56
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  56

Ser Pro Gly Met Met Met Gly Met Phe 
1               5                   


<210>  57
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  57

Glu Arg Gly Lys Leu Lys Arg Arg Ala Ile Ala Thr Pro Gly Met Gln 
1               5                   10                  15      


<210>  58
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  58

Ser Ser Leu Cys Pro Ile Arg Gly Trp Ala Ile His Ser Lys 
1               5                   10                  


<210>  59
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  59

Gly Glu Ala Pro Ser Pro Tyr Asn Ser Arg Phe 
1               5                   10      


<210>  60
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  60

Val Gly Glu Ala Pro Ser Pro Tyr Asn Ser Arg Phe Glu Ser Val Ala 
1               5                   10                  15      


Trp 
    


<210>  61
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  61

Gly Pro Asp Asp Gly Ala Val Ala Val Leu 
1               5                   10  


<210>  62
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  62

Gly Ala Val Ala Val Leu Lys Tyr 
1               5               


<210>  63
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  63

Trp His Ser Asn Leu Asn Asp Ala Thr Tyr 
1               5                   10  


<210>  64
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  64

Ala Thr Tyr Gln Arg Thr Arg Ala Leu 
1               5                   


<210>  65
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  65

Ala Thr Tyr Gln Arg Thr Arg Ala Leu Val 
1               5                   10  


<210>  66
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  66

Tyr Glu Arg Met Cys Asn Ile Leu 
1               5               


<210>  67
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  67

Ala Tyr Glu Arg Met Cys Asn Ile Leu Lys Gly Lys Phe 
1               5                   10              


<210>  68
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  68

Lys Arg Gly Ile Asn Asp Arg Asn Phe Trp 
1               5                   10  


<210>  69
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  69
gacgatgcaa cggctggtct g                                                 21


<210>  70
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  70
accattgttc caactccttt                                                   20


<210>  71
<211>  24
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  71
cggaaaggat gctggccctt taac                                              24


<210>  72
<211>  22
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  72
tccgtttcat taccaacacc ac                                                22


<210>  73
<211>  23
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  73
tcctggatcc ccaaaagaaa tcg                                               23


<210>  74
<211>  23
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  74
tccagattcg aaatcaattc gtg                                               23


<210>  75
<211>  23
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  75
aagtactggc agaactgcag gac                                               23


<210>  76
<211>  22
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  76
aatccaactt gcaagcgacc tc                                                22


<210>  77
<211>  23
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  77
aacatgggag gatgaactat tac                                               23


<210>  78
<211>  23
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  78
agggagattg ctgtttatag ctc                                               23


<210>  79
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  79
atggagcaaa cggagtaaag g                                                 21


<210>  80
<211>  23
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  80
ttgaacgaaa cttccgctgt acc                                               23


<210>  81
<211>  23
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  81
actcatccta gctccagtgc tgg                                               23


<210>  82
<211>  24
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  82
tttcaaaccg tatttaaagc gacg                                              24


<210>  83
<211>  23
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  83
aagtggcagg ccctctttgt atc                                               23


<210>  84
<211>  23
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  84
ccaactgcat ttttgacatc ctc                                               23


<210>  85
<211>  12
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  85
agcgaaagca gg                                                           12


<210>  86
<211>  13
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  86
agtagaaaca agg                                                          13


<210>  87
<211>  19
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  87
ccagggattt cagtcgatg                                                    19


<210>  88
<211>  19
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  88
aatctcacgc aggcagttc                                                    19


<210>  89
<211>  28
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide


<220>
<221>  misc_feature
<222>  (23)..(28)
<223>  n is a, c, g, or t

<400>  89
ctacacgacg ctcttccgat ctnnnnnn                                          28


<210>  90
<211>  28
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide


<220>
<221>  misc_feature
<222>  (23)..(28)
<223>  n is a, c, g, or t

<400>  90
tgctgaaccg ctcttccgat ctnnnnnn                                          28


<210>  91
<211>  54
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  91
aatgatacgg cgaccaccga gatctacact ctttccctac acgacgctct tccg             54


<210>  92
<211>  57
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  92
caagcagaag acggcatacg agatcggtct cggcattcct gctgaaccgc tcttccg          57


<210>  93
<211>  24
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Residue is selected from the group consisting of S, I, T, Y, H, 
       K, N, D, and analogs and isomers  thereof, preferably S, I, T, H,
       K, N, or D

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Residue is selected from the group consisting of I, P, H, F, V, 
       L, R, and analogs and isomers  thereof, preferably I, F, V, L, or
       R

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Residue is selected from the group consisting of P, V, S, E, G, 
       A, T, and analogs thereof, preferably P, V, S, E, G, A or T

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Residue is selected from the group consisting of K, R, I, T, Q, 
       N, E, and analogs and isomers thereof, preferably K, R, I, T, Q, 
       N or E

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Residue is selected from the group consisting of R, V, E, G, A, 
       and analogs and isomers thereof, preferably R, V, E, or A

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Residue is selected from the group consisting of Q, D, V, K, G, 
       E, A, and analogs and isomers thereof, preferably D, K, G, E, or 
       A

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Residue is selected from the group consisting of N, M, E, K, R, 
       T, Q, and analogs and isomers thereof, preferably N, E, K, T, or 
       Q

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Residue is selected from the group consisting of G, P, D, A, T, 
       V, S, and analogs and isomers thereof, preferably A or T

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  Residue is selected from the group consisting of T, H, Y, K, N, 
       S, D, I, and analogs and isomers thereof, preferably T, K, N or S

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Residue is selected from the group consisting of E, V, L, M, G, 
       A, and analogs and isomers thereof, preferably E, V, L, M, or A

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  Residue is selected from the group consisting of Q, R, V, I, L, 
       P, and analogs and isomers thereof, preferably Q, R, V, I, L or P

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Residue is selected from the group consisting of V, L, M, S, I, 
       T, N, F, and analogs and isomers thereof, preferably V, L, M, S, 
       T or N

<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  Residue is selected from the group consisting of G, A, E, V, W, 
       R, and analogs and isomers thereof, preferably W

<220>
<221>  MISC_FEATURE
<222>  (14)..(14)
<223>  Residue is selected from the group consisting of P, Q, E, H, L, 
       R, K, and analogs and isomers thereof, preferably K

<220>
<221>  MISC_FEATURE
<222>  (15)..(15)
<223>  Residue is selected from the group consisting of G, A, E, R, V, 
       and analogs and isomers thereof, preferably E or V

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Residue is selected from the group consisting of G, A, N, H, E, 
       D, Y, V, and analogs and isomers thereof, preferably Y

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Residue is selected from the group consisting of A, L, M, G, E, 
       V, I and analogs and isomers thereof, preferably I, L or V

<220>
<221>  MISC_FEATURE
<222>  (18)..(18)
<223>  Residue is selected from the group consisting of E, A, M, L, V, 
       G, and analogs and isomers thereof, preferably A, M, L or G

<220>
<221>  MISC_FEATURE
<222>  (19)..(19)
<223>  Residue is selected from the group consisting of S, M, V, F, L, 
       W, and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (20)..(20)
<223>  Residue is selected from the group consisting of G, A, L, E, V, 
       I, and analogs and isomers thereof, preferably G, E, V or I

<220>
<221>  MISC_FEATURE
<222>  (21)..(21)
<223>  Residue is selected from the group consisting of I, L, R, T, K, 
       V, and analogs and isomers thereof, preferably I, L, R, T, K or V

<220>
<221>  MISC_FEATURE
<222>  (22)..(22)
<223>  Residue is selected from the group consisting of K, N, E, R, Q, 
       T, I, and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (23)..(23)
<223>  Residue is selected from the group consisting of L, Q, P, W, G, 
       R, and analogs and isomers thereof, preferably R

<220>
<221>  MISC_FEATURE
<222>  (24)..(24)
<223>  Residue is selected from the group consisting of N, K, T, Q, R, 
       E, I, and analogs and isomers thereof, preferably R

<400>  93

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10                  15      


Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
            20                  


<210>  94
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Residue A1 is selected from the group consisting of A, G, E, and 
       analogs and isomers thereof, preferably A1 is A or E

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Residue Y2 is selected from the group consisting of F, H, N, C, 
       D, Y, S, and analogs and isomers thereof, preferably Y2 is F, H, 
       C, D, Y or S

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Residue M3 is selected from the group consisting of T, V, R, L, 
       K, I, and analogs and isomers thereof, preferably M3 is T, V, L 
       or I

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Residue L4 is selected from the group consisting of F, L, M, V, 
       W, S, and analogs and isomers thereof, preferably L4 is L or M

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Residue E5 is selected from the group consisting of Q, V, A, G, 
       D, E, K, and analogs and isomers thereof, preferably E5 is Q, D, 
       E or K

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Residue R6 is selected from the group consisting of G, K, I, R, 
       S, T, and analogs and isomers thereof, preferably R6 is R

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Residue E7 is selected from the group consisting of A, G, E, D, 
       K, Q, V, and analogs and isomers thereof, preferably E7 is A, G, 
       E, D or K

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Residue L8 is selected from the group consisting of V, Q, M, L, 
       P, R, and analogs and isomers thereof, preferably L8 is L

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  Residue V9 is selected from the group consisting of D, A, V, F, 
       G, L, I, and analogs and isomers thereof, preferably V9 is A, V, 
       F, L or I

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Residue R10 is selected from the group consisting of G, H, L, C, 
       S, R, P, and analogs and isomers thereof, preferably R10 is G, H,
       S, R or P

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  Residue K11 is selected from the group consisting of E, I, K, N, 
       Q, R, T, and analogs and isomers thereof, preferably K11 is E, K,
       N, Q, R or T

<400>  94

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10      


<210>  95
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  I1 is selected from the group consisting of L, I, T, V, R, K or 
       M, and analogs and isomers thereof, preferably I1 is L or V

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  L2 is selected from the group consisting of R, L, H, I, F, P, or 
       V, and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  T3 is selected from the group consisting of S, N, A, P, T, or I, 
       and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D4 is selected from the group consisting of Y, H, N, G, D, E, A, 
       or V, and analogs and isomers thereof, preferably D4 is Y

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  S5 is selected from the group consisting of G, R, T, C, I, N, or 
       S, and analogs and isomers thereof, preferably S5 is C

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Q6 is selected from the group consisting of K, H, Q, P, E, L, or 
       R, and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  T7 is selected from the group consisting of S, A, T, R, K, I, or 
       P, and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  A8 is selected from the group consisting of T, A, E, G, P, S, or 
       V, and analogs and isomers thereof, preferably A8 is A

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  T9 is selected from the group consisting of I, P, A, N, S, or T, 
       and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  K10 is selected from the group consisting of E, T, K, N, Q, I, or
       R, and analogs and isomers thereof, preferably K10 is T, I or R

<400>  95

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10  


<210>  96
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Y1 is selected from the group consisting of N, H, D, F, C, Y or 
       S, and analogs and isomers thereof, preferably Y1 is F or Y

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  S2 is selected from the group consisting of I, N, C, G, S, R or 
       T, and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  H3 is selected from the group consisting of Y, Q, P, R, L, N, H 
       or D, and analogs and isomers thereof, preferably H3 is R or H

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  G4 is selected from the group consisting of G, A, W, V, R or E, 
       and analogs and isomers thereof, preferably G4 is G or W

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  T5 is selected from the group consisting of K, I, A, T, S, R or 
       P, and analogs and isomers thereof, preferably T5 is T or S

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  G6 is selected from the group consisting of R, V, A, G or E, and 
       analogs and isomers thereof, preferably G6 is V or G

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  T7 is selected from the group consisting of T, P, S, R, A, I or 
       K, and analogs and isomers thereof, preferably T7 is T or A

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  G8 is selected from the group consisting of A, G, E, R or V, and 
       analogs and isomers thereof, preferably G8 is G or V

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  Y9 is selected from the group consisting of Y, D, F, C, N, H or 
       S, and analogs and isomers thereof, preferably Y9 is Y or H

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  T10 is selected from the group consisting of P, S, T, I, N or A, 
       and analogs and isomers thereof, preferably T10 is T

<400>  96

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10  


<210>  97
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  E1 is present or absent, and if present E1 is selected from the 
       group consisting of K, D, A, V, Q, G or E, and analogs and 
       isomers thereof, preferably E1 is D or E

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  R2 is selected from the group consisting of T, K, I, G, S or R, 
       and analogs and isomers thereof, preferably R2 is I or R

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  G3 is selected from the group consisting of W, V, R, G, E or A, 
       and analogs and isomers thereof, preferably G3 is W, G or E

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  K4 is selected from the group consisting of E, M, N, K, T, Q or 
       R, and analogs and isomers thereof, preferably K4 is K

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  L5 is selected from the group consisting of R, L, P, Q, V or I, 
       and analogs and isomers thereof, preferably L5 is L

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  K6 is selected from the group consisting of T, R, Q, N, K, I or 
       E, and analogs and isomers thereof, preferably K6 is T, R or K

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  R7 is selected from the group consisting of L, G, R, P, Q or W, 
       and analogs and isomers thereof, preferably R7 is R

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  R8 is selected from the group consisting of K, I, G, S, R or T, 
       and analogs and isomers thereof, preferably R8 is I or R

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  A9 is selected from the group consisting of V, A, G, E, S, P or 
       T, and analogs and isomers thereof, preferably A9 is A, E or S

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  I10 is selected from the group consisting of S, T, F, I, M, L, N 
       or V, and analogs and isomers thereof, preferably I10 is I

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  A11 is selected from the group consisting of T, V, A, P, S, E or 
       G, and analogs and isomers thereof, preferably A11 is A or S

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  T12 is  selected from the group consisting of S, P, N, A, T or I,
       and analogs and isomers thereof, preferably T12 is S or T

<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  P13 is selected from the group consisting of A, L, S, R, Q, T or 
       P, and analogs and isomers thereof, preferably P13 is Q, T or P

<220>
<221>  MISC_FEATURE
<222>  (14)..(14)
<223>  G14 is selected from the group consisting of G, E, A, W, V or R, 
       and analogs and isomers thereof, preferably G14 is G, W or V

<220>
<221>  MISC_FEATURE
<222>  (15)..(15)
<223>  M15 is selected from the group consisting of I, K, T, V, L or R, 
       and analogs and isomers thereof, preferably M15 is I or V

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Q16 is selected from the group consisting of R, Q, P, K, H, L or 
       E, and analogs and isomers thereof, preferably Q16 is K

<400>  97

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10                  15      


<210>  98
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N1 is selected from the group consisting of D, H, I, Y, K, T, S 
       or N, and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  E2 is selected from the group consisting of G, V, A, D, E, K or 
       Q, and analogs and isomers thereof, preferably E2 is G, E or Q

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  K3 is selected from the group consisting of R, Q, T, E, K, N or 
       M, and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  K4 is selected from the group consisting of T, Q, R, N, K, E or 
       I, and analogs and isomers thereof, preferably K4 is K or E

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  A5 is selected from the group consisting of V, T, S, P, G, E or 
       A, and analogs and isomers thereof, preferably A5 is E or A

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  K6 is selected from the group consisting of R, E, M, Q, K, N or 
       T, and analogs and isomers thereof, preferably K6 is R or K

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  L7 is selected from the group consisting of S, W, V, F, M or L, 
       and analogs and isomers thereof, preferably L7 is W, F or L

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  A8 is selected from the group consisting of S, P, V, T, A, G or 
       E, and analogs and isomers thereof, preferably A8 is G or E

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  N9 is selected from the group consisting of I, H, K, N, D, Y, S 
       or T, and analogs and isomers thereof, preferably N9 is N

<400>  98

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   


<210>  99
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  S1 is selected from the group consisting of G, R, T, S, C, N or 
       I, and analogs and isomers thereof, preferably S1 is S

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  P2 is selected from the group consisting of A, L, H, T, R, S or 
       P, and analogs and isomers thereof, preferably P2 is P

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  G3 is selected from the group consisting of G, A, E, R or V, and 
       analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  M4 is selected from the group consisting of M, T, I, V, L, R or 
       K, and analogs and isomers thereof, preferably M4 is I or V

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  M5 is selected from the group consisting of L, I, K, V, R or T, 
       and analogs and isomers thereof, preferably M5 is I

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  M6 is selected from the group consisting of L, I, K, R, V or T, 
       and analogs and isomers thereof, preferably M6 is I

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  G7 is selected from the group consisting of G, C, S, R, A, V or 
       D, and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  M8 is selected from the group consisting of L, T, R, I, V or K, 
       and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  F9 is selected from the group consisting of S, Y, F, C, I, V or 
       L, and analogs and isomers thereof, preferably F9 is F or L

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  N10  is present or absent, and if present N10 is selected from 
       the group consisting of S, T, Y, D, K, I, H or N, and analogs and
       isomers thereof

<400>  99

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10  


<210>  100
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  G1 is selected from the group consisting of G, C, A, R, S, V or 
       D, and analogs and isomers thereof, preferably G1 is G or C

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  L2 is selected from the group consisting of R, P, V, F, H, L or 
       I, and analogs and isomers thereof, preferably L2 is V, L or I

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Q3 is selected from the group consisting of P, E, R, Q, L, K or 
       H, and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  S4 is selected from the group consisting of Y, S, P, T, C, A or 
       F, and analogs and isomers thereof, preferably S4 is Y, S or A

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  S5 is selected from the group consisting of T, S, C, Y, A, F or 
       P, and analogs and isomers thereof, preferably S5 is S

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  D6 is selected from the group consisting of N, G, D, E, A, H, V 
       or Y, and analogs and isomers thereof, preferably D6 is Y

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  D7 is selected from the group consisting of D, A, G, E, H, N, V 
       or Y, and analogs and isomers thereof, preferably D7 is A, G or Y

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  F8 is selected from the group consisting of I, C, S, L, F, V or 
       Y, and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  A9 is selected from the group consisting of D, G, A, S, T, P or V
       and analogs and isomers thereof, preferably A9 is A, S or V

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  L10 is selected from the group consisting of R, P, V, L, M or Q, 
       and analogs and isomers thereof, preferably L10 is L or M

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  I11 is selected from the group consisting of I, F, T, L, V, S, M 
       or N, and analogs and isomers thereof, preferably I11 is L or M

<400>  100

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10      


<210>  101
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  K1is selected from the group consisting of T, R, Q, N, M, K or E,
       and analogs and isomers thereof, preferably K1 is R

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  L2 is selected from the group consisting of R, P, V, Q, I or L, 
       and analogs and isomers thereof, preferably L2 is L

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  L3 is selected from the group consisting of R, F, H, V, P, L or 
       I, and analogs and isomers thereof, preferably L3 is L or I

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  G4 is selected from the group consisting of E, A, R, V or G, and 
       analogs and isomers thereof, preferably G4 is E, V or G

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  I5 is selected from the group consisting of F, L, M, T, S, N, I 
       or V, and analogs and isomers thereof, preferably I5 is L or M

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  N6 is selected from the group consisting of Y, D, I, T, S, N, K 
       or H, and analogs and isomers thereof, preferably N6 is T or N

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  M7 is selected from the group consisting of R, V, T, K, I or L, 
       and analogs and isomers thereof, preferably M7 is V or I

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  S8 is selected from the group consisting of T, R, S, N, I, G or 
       C, and analogs and isomers thereof, preferably S8 is S

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  K9 is selected from the group consisting of E, N, M, K, T, R or 
       Q, and analogs and isomers thereof, preferably K9 is K

<400>  101

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   


<210>  102
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N1 is selected from the group consisting of T, S, N, H, K, D, Y 
       or I, and analogs and isomers thereof, preferably N1 is T or N

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  R2 is selected from the group consisting of T, K, G, I, S or R, 
       and analogs and isomers thereof, preferably R2 is I or R

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  T3 is selected from the group consisting of A, I, K, P, R, S or 
       T, and analogs and isomers thereof, preferably T3 is S or T

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  G4 is selected from the group consisting of D, V, R, S, A, G or 
       C, and analogs and isomers thereof, preferably G4 is G or C

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  T5 is selected from the group consisting of A, T, R, S, K, I or 
       P, and analogs and isomers thereof, preferably T5 is T or K

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  F6 is selected from the group consisting of I, V, S, Y, F, C or 
       L, and analogs and isomers thereof, preferably F6 is F

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  E7 is selected from the group consisting of V, K, G, D, E, A or 
       Q, and analogs and isomers thereof, preferably E7 is E

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  F8 is selected from the group consisting of Y, V, S, L, I, F or 
       C, and analogs and isomers thereof, preferably F8 is L or F

<400>  102

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5               


<210>  103
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N1 is selected from the group consisting of S, T, Y, D, I, H, K 
       or N, and analogs and isomers thereof, preferably N1 is D or N

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  E2 is selected from the group consisting of Q, K, A, E, D, G or 
       V, and analogs and isomers thereof, preferably E2 is E

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  S3 is selected from the group consisting of Y, S, A, F, P, T or 
       C, and analogs and isomers thereof, preferably S3 is Y, S or P

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  A4 is selected from the group consisting of P, E, V, T, S, A or 
       G, and analogs and isomers thereof, preferably A4 is V or A

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D5 is selected from the group consisting of E, H, G, D, Y, N, A 
       or V, and analogs and isomers thereof, preferably D5 is G, D or Y

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  M6 is selected from the group consisting of T, R, K, I, L or V, 
       and analogs and isomers thereof, preferably M6 is I

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  S7 is selected from the group consisting of N, R, G, C, I, T or 
       S, and analogs and isomers thereof, preferably S7 is G

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  I8 is selected from the group consisting of S, V, T, F, I, N, L 
       or M, and analogs and isomers thereof, preferably I8 is V

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  G9 is selected from the group consisting of E, G, R, V or A, and 
       analogs and isomers thereof, preferably G9 is G or V

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  V10 is selected from the group consisting of A, G, F, D, V, I or 
       L, and analogs and isomers thereof, preferably V10 is V or I

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  T11 is selected from the group consisting of S, I, T, P, N or A, 
       and analogs and isomers thereof, preferably T11 is S, T or A

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  V12 is selected from the group consisting of A, G, F, V, D, I or 
       L, and analogs and isomers thereof, preferably V12 is A or V

<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  I13 is selected from the group consisting of F, I, T, L, S, M, V 
       or N, and analogs and isomers thereof, preferably I13 is I or L

<400>  103

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10              


<210>  104
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  L1 is selected from the group consisting of L, H, F, V, R, P or 
       I, and analogs and isomers thereof, preferably L1 is L or I

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  G2 is selected from the group consisting of G, S, R, A, C, D or 
       V, and analogs and isomers thereof, preferably G2 is G or C

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  P3 is selected from the group consisting of P, A, L, T, Q, S or 
       R, and analogs and isomers thereof, preferably P3 is P or T

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  A4 is selected from the group consisting of P, A, G, T, V, S or 
       E, and analogs and isomers thereof, preferably A4 is A, S or E

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  T5 is selected from the group consisting of S, P, N, I, A, T, and
       analogs and isomers thereof, preferably T5 is T

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  A6 is selected from the group consisting of D, A, T, S, G, V or 
       P, and analogs and isomers thereof, preferably A6 is A or T

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Q7 is selected from the group consisting of R, H, P, Q, E, K or 
       L, and analogs and isomers thereof, preferably Q7 is Q or K

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  M8 is selected from the group consisting of T, V, I, R, L or K, 
       and analogs and isomers thereof, preferably M8 is I or L

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  A9 is selected from the group consisting of S, T, A, P, V, G or 
       D, and analogs and isomers thereof, preferably A9 is S

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  L10 is selected from the group consisting of V, L, F, H, R, I or 
       P, and analogs and isomers thereof, preferably L10 is I

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  Q11 is selected from the group consisting of K, Q, H, P, R, L or 
       E, and analogs and isomers thereof, preferably Q11 is K or Q

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  L12 is selected from the group consisting of M, L, V, R, P or Q, 
       and analogs and isomers thereof, preferably L12 is L

<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  F13 is selected from the group consisting of V, C, I, F, L, S or 
       Y, and analogs and isomers thereof, preferably F13 is L

<220>
<221>  MISC_FEATURE
<222>  (14)..(14)
<223>  I14 is selected from the group consisting of T, L, N, I, M, F, V 
       or S, and analogs and isomers thereof, preferably I14 is I or V

<220>
<221>  MISC_FEATURE
<222>  (15)..(15)
<223>  K15 is selected from the group consisting of N, E, K, R, T, Q or 
       I, and analogs and isomers thereof, preferably K15 is K

<400>  104

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10                  15  


<210>  105
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  E1 is selected from the group consisting of K, D, E, V, Q, G or 
       A, and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  M2 is selected from the group consisting of T, V, R, L, I or K, 
       and analogs and isomers thereof, preferably M2 is R

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  A3 is selected from the group consisting of P, S, T, V, A, D or 
       G, and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  T4 is selected from the group consisting of A, K, I, T, R, S or 
       P, and analogs and isomers thereof, preferably T4 is S

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  K5 is selected from the group consisting of Q, E, K, M, N, R or 
       T, and analogs and isomers thereof, preferably K5 is N or T

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  A6 is selected from the group consisting of T, V, P, S, D, G or 
       A, and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  D7 is selected from the group consisting of Y, V, N, H, D, E, G 
       or A, and analogs and isomers thereof, preferably D7 is Y

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Y8 is selected from the group consisting of N, H, F, D, C, Y or 
       S, and analogs and isomers thereof, preferably Y8 is D

<400>  105

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5               


<210>  106
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Y1 is selected from the group consisting of Y, S, H, N, C, D or 
       F, and analogs and isomers thereof, preferably Y1 is Y, S or F

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  H2 is selected from the group consisting of D, L, N, H, Q, P, R 
       or Y, and analogs and isomers thereof, preferably H2 is L, N, H, 
       or Q

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  A3 is selected from the group consisting of A, G, S, P, V, T or 
       E, and analogs and isomers thereof, preferably A3 is A

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  N4 is selected from the group consisting of Y, S, T, K, N, D, I 
       or H, and analogs and isomers thereof, preferably N4 is N

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  N5 is selected from the group consisting of T, S, Y, D, N, H, I 
       or K, and analogs and isomers thereof, preferably N5 is N

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  S6 is selected from the group consisting of L, A, T, P or S, and 
       analogs and isomers thereof, preferably S6 is S

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  T7 is selected from the group consisting of S, P, T, A, I or N, 
       and analogs and isomers thereof, preferably T7 is T or N

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  D8 is selected from the group consisting of V, E, A, D, G, H, N 
       or Y, and analogs and isomers thereof, preferably D8 is E, D or Y

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  T9 is selected from the group consisting of P, S, T, I, N or A, 
       and analogs and isomers thereof, preferably T9 is S or T

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  V10 is selected from the group consisting of I, V, D, F, G, A or 
       L, and analogs and isomers thereof, preferably V10 is I or V

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  D11 is selected from the group consisting of Y, V, N, H, G, E, D 
       or A, and analogs and isomers thereof, preferably D11 is Y or D

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  T12 is selected from the group consisting of I, K, A, T, P, R or 
       S, and analogs and isomers thereof, preferably T12 is T

<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  I13 is selected from the group consisting of L, M, K, I, V, T or 
       R, and analogs and isomers thereof, preferably I13 is I

<220>
<221>  MISC_FEATURE
<222>  (14)..(14)
<223>  L14 is selected from the group consisting of R, P, V, F, H, I or 
       L, and analogs and isomers thereof, preferably L14 is I or L

<220>
<221>  MISC_FEATURE
<222>  (15)..(15)
<223>  E15 is selected from the group consisting of A, D, E, G, K, Q or 
       V, and analogs and isomers thereof, preferably E15 is D, E or K

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  K16 is selected from the group consisting of K, M, N, E, Q, R or 
       T, and analogs and isomers thereof, preferably K16 is K or N

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  N17 is selected from the group consisting of Y, S, T, K, H, N, D 
       or I, and analogs and isomers thereof, preferably N17 is H or D

<220>
<221>  MISC_FEATURE
<222>  (18)..(18)
<223>  V18 is selected from the group consisting of M, V, L, E, G or A, 
       and analogs and isomers thereof, preferably V18 is V

<400>  106

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10                  15      


Xaa Xaa 
        


<210>  107
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  W1 is selected from the group consisting of S, R, L, C or G, and 
       analogs and isomers thereof, preferably W1 is L

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  H2 is selected from the group consisting of R, P, Q, Y, D, H, N 
       or L, and analogs and isomers thereof, preferably H2 is H

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  S3 is selected from the group consisting of Y, S, P, T, C, A or 
       F, and analogs and isomers thereof, preferably S3 is Y or S

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  N4 is selected from the group consisting of T, I, S, Y, D, K, H 
       or N, and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  L5 is selected from the group consisting of V, S, W, F, M or L, 
       and analogs and isomers thereof, preferably L5 is F or L

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  N6 is selected from the group consisting of T, S, Y, D, N, H, I 
       or K, and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  D7 is selected from the group consisting of V, Y, A, E, D, G, H 
       or N, and analogs and isomers thereof, preferably D7 is Y or D

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  A8 is selected from the group consisting of T, V, P, S, E, G or 
       A, and analogs and isomers thereof, preferably A8 is S

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  T9 is selected from the group consisting of N, I, A, T, S or P, 
       and analogs and isomers thereof, preferably T9 is T

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Y10 is selected from the group consisting of F, D, C, N, H, S or 
       Y, and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  Q11 is selected from the group consisting of H, K, L, E, P, Q or 
       R, and analogs and isomers thereof, preferably Q11 is Q

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  R12 is selected from the group consisting of T, W, S, R, G, M or 
       K, and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  T13 is selected from the group consisting of P, R, S, T, A, I or 
       K, and analogs and isomers thereof, preferably T13 is K

<220>
<221>  MISC_FEATURE
<222>  (14)..(14)
<223>  R14 is selected from the group consisting of S, R, T, G, K or I, 
       and analogs and isomers thereof, preferably R14 is R

<220>
<221>  MISC_FEATURE
<222>  (15)..(15)
<223>  A15 is selected from the group consisting of A, G, D, S, P, V or 
       T, and analogs and isomers thereof, preferably A15 is A or S

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  L16 is selected from the group consisting of R, P, V, I, H, L or 
       F, and analogs and isomers thereof, preferably L16 is I or L

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  V17 is selected from the group consisting of V, F, G, D, A, L or 
       I, and analogs and isomers thereof, preferably V17 is V

<400>  107

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10                  15      


Xaa 
    


<210>  108
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  K1 is present or absent, and if present K1 is selected from the 
       group consisting of K, N, I, E, T, Q or R, and analogs and 
       isomers thereof, preferably K1 is R

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  R2 is selected from the group consisting of S, H, R, P, G, C or 
       L, and analogs and isomers thereof, preferably R2 is R

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  G3 is selected from the group consisting of R, V, W, A, E or G, 
       and analogs and isomers thereof, preferably G3 is W or G

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  I4 is selected from the group consisting of T, V, S, F, M, L, N 
       or I, and analogs and isomers thereof, preferably I4 is T, M or I

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  N5 is selected from the group consisting of K, I, H, N, D, Y, S 
       or T, and analogs and isomers thereof, preferably N5 is N, S or T

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  D6 is selected from the group consisting of A, G, Y, H, D, E, N 
       or V, and analogs and isomers thereof, preferably D6 is Y or D

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  R7 is selected from the group consisting of G, L, W, Q, P or R, 
       and analogs and isomers thereof, preferably R7 is R

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  N8 is selected from the group consisting of D, S, T, Y, K H, I or
       N, and analogs and isomers thereof, preferably N8 is N

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  F9 is selected from the group consisting of I, V, S, Y, F, C or 
       L, and analogs and isomers thereof, preferably F9 is L

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  W10 is selected from the group consisting of L, S, G, C or R, and
       analogs and isomers thereof

<400>  108

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10  


<210>  109
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  A1 is present or absent, and if present A1 is selected from the 
       group consisting of V, P, A, T, S, G or D, and analogs and 
       isomers thereof, preferably A1 is A

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Y2 is selected from the group consisting of H, S, C, D, F, N or 
       Y, and analogs and isomers thereof, preferably Y2 is S

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  E3 is selected from the group consisting of A, D, G, K, Q, V or 
       E, and analogs and isomers thereof, preferably E3 is E

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  R4 is selected from the group consisting of G, I, K, T, R or S, 
       and analogs and isomers thereof, preferably R4 is I or K

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  M5 is selected from the group consisting of R, V, T, K, I or L, 
       and analogs and isomers thereof, preferably M5 is I

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  C6 is selected from the group consisting of C, G, F, Y, S, R or 
       W, and analogs and isomers thereof, preferably C6 is C

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  N7 is selected from the group consisting of Y, I, N, D, S, K, H 
       or T, and analogs and isomers thereof, preferably N7 is K

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  I8 is selected from the group consisting of I, F, S, N, M, L, T 
       or V, and analogs and isomers thereof, preferably I8 is V

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  L9 is selected from the group consisting of V, R, P, L, H, F or 
       I, and analogs and isomers thereof, preferably L9 is L or I

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  K10 is present or absent, and if present, K10 is selected from 
       the group consisting of E, N, K, I, T, R or Q, and analogs and 
       isomers thereof, preferably K10 is K

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  G11 is present or absent, and if present G11 is selected from the
       group consisting of G, W, A, E, R or V, and analogs and isomers 
       thereof, preferably G11 is G or V

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  K12 is present or absent, and if present K12 is selected from the
       group consisting of I, K, E, T, Q, R or N, and analogs and 
       isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  F13 is present or absent, and if present F13 is selected from the
       group consisting of Y, V, S, L, I, C or F, and analogs and 
       isomers thereof, preferably F13 is L

<220>
<221>  MISC_FEATURE
<222>  (14)..(14)
<223>  Q14 is present or absent, and if present, Q14 is selected from 
       the group consisting of E, L, K, H, R, P or Q, and analogs and 
       isomers thereof, preferably Q14 is K or Q

<220>
<221>  MISC_FEATURE
<222>  (15)..(15)
<223>  T15 is present or absent, and if present T15 is selected from the
       group consisting of K, I, A, T, R, S or P, and analogs and 
       isomers thereof, preferably T15 is I, T or S

<400>  109

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10                  15  


<210>  110
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  E1 is selected from the group consisting of Q, V, D, E, K, A or 
       G, and analogs and isomers thereof, preferably E1 is Q

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  L2 is selected from the group consisting of V, Q, P, M, L or R, 
       and analogs and isomers thereof, preferably L2 is M or L

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  R3 is selected from the group consisting of G, I, K, R, T or S, 
       and analogs and isomers thereof, preferably R3 is R

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  S4 is selected from the group consisting of G, C, N, I, T, R or 
       S, and analogs and isomers thereof, preferably S4 is S

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  R5 is selected from the group consisting of T, K, R, S, G or I, 
       and analogs and isomers thereof, preferably R5 is K, R or I

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Y6 is selected from the group consisting of H, C, F, D, Y, N or 
       S, and analogs and isomers thereof, preferably Y6 is H or Y

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  W7 is selected from the group consisting of C, S, G, L or R, and 
       analogs and isomers thereof, preferably W7 is L

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  A8 is selected from the group consisting of P, A, D, G, S, T or 
       V, and analogs and isomers thereof, preferably A8 is A

<400>  110

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5               


<210>  111
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  S1 is selected from the group consisting of A, F, T, Y, C, S or 
       P, and analogs and isomers thereof, preferably S1 is S

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  F2 is selected from the group consisting of F, I, S, L, V, Y or 
       C, and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Q3 is selected from the group consisting of L, H, E, R, Q, K or 
       P, and analogs and isomers thereof, preferably Q3 is H or Q

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  G4 is selected from the group consisting of R, V, A, E, G or W, 
       and analogs and isomers thereof, preferably G4 is R or W

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  R5 is selected from the group consisting of G, Q, L, W, R or P, 
       and analogs and isomers thereof, preferably R5 is R or P

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  G6 is selected from the group consisting of A, G, E, R or V, and 
       analogs and isomers thereof, preferably G6 is V

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  V7 is selected from the group consisting of I, L, A, F, V, G or 
       D, and analogs and isomers thereof, preferably V7 is L or V

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  F8 is selected from the group consisting of S, V, L, I, C, Y or 
       F, and analogs and isomers thereof, preferably F8 is F

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  E9 is selected from the group consisting of E, D, K, Q, A, V or 
       G, and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  L10 is selected from the group consisting of P, I, H, L, F, R or 
       V, and analogs and isomers thereof

<400>  111

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10  


<210>  112
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  L1 is selected from the group consisting of V, P, R, L, I, H or 
       F, and analogs and isomers thereof, preferably L1 is L or I

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  S2 is selected from the group consisting of F, C, Y, T, S, A or 
       P, and analogs and isomers thereof, preferably S2 is C, Y, T, S 
       or A

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  T3 is selected from the group consisting of A, N, T, S, P, or I, 
       and analogs and isomers thereof, preferably T3 is T or S

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  R4 is selected from the group consisting of I, K, G, S, R or T, 
       and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  G5 is selected from the group consisting of R, A, G, E or V, and 
       analogs and isomers thereof, preferably G5 is V

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  V6 is selected from the group consisting of F, V, D, G, I, L or 
       A, and analogs and isomers thereof, preferably V6 is F, V or A

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Q7 is selected from the group consisting of Q, L, E, K, H, R or 
       P, and analogs and isomers thereof, preferably Q7 is Q, K or P

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  I8 is selected from the group consisting of S, T, V, I, L, M, N 
       or F, and analogs and isomers thereof, preferably I8 is V, I or L

<400>  112

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5               


<210>  113
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  G1 is present or absent, and if present G1 is selected from the 
       group consisting of C, A, G, D, R, S or V, and analogs and 
       isomers thereof, preferably G1 is C or G

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  P2 is present or absent, and if present P2 is selected from the 
       group consisting of L, A, T, P, Q, R or S, and analogs and 
       isomers thereof, preferably P2 is T, P or Q

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  D3 is present or absent, and if present D3 is selected from the 
       group consisting of Y, V, N, H, G, E, D or A, and analogs and 
       isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D4 is present or absent, and if present D4 is selected from the 
       group consisting of N, H, G, D, E, A, Y or V, and analogs and 
       isomers thereof, preferably D4 is D or Y

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  G5 is selected from the group consisting of V, R, G, E or A, and 
       analogs and isomers thereof, preferably G5 is V or G

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  A6 is selected from the group consisting of P, S, T, V, A, E or 
       G, and analogs and isomers thereof, preferably A6 is A

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  V7 is selected from the group consisting of V, M, L, A, E or G, 
       and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  A8 is selected from the group consisting of S, P. V, T, A, G or 
       D, and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  V9 is selected from the group consisting of I, L, A, G, E or V, 
       and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  L10 is selected from the group consisting of F, I, L, S or V, and
       analogs and isomers thereof, preferably L10 is I, L or V

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  K11 is selected from the group consisting of R, Q, T, K, I, N or 
       E, and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Y12 is selected from the group consisting of C, D, F, H, N, S or 
       Y, and analogs and isomers thereof, preferably Y12 is Y

<400>  113

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10          


<210>  114
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  F1 is selected from the group consisting of L, I, F, C, Y, V or 
       S, and analogs and isomers thereof, preferably F1 is F

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  V2 is selected from the group consisting of D, F, G, A, L, I or 
       V, and analogs and isomers thereof, preferably V2 is F or V

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  I3 is selected from the group consisting of T, V, R, L, M, I or 
       K, and analogs and isomers thereof, preferably I3 is T or R

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  R4 is selected from the group consisting of R, T, G, K, I or S, 
       and analogs and isomers thereof, preferably R4 is I

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  E5 is selected from the group consisting of A, G, D, E, K, Q or 
       V, and analogs and isomers thereof, preferably E5 is D or E

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  P6 is selected from the group consisting of H, L, A, R, S, P or 
       T, and analogs and isomers thereof, preferably P6 is P or T

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  F7 is selected from the group consisting of Y, V, S, L, I, F, or 
       C, and analogs and isomers thereof, preferably F7 is S, L or F

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  I8 is selected from the group consisting of V, N, S, T, F, I, M 
       or L, and analogs and isomers thereof, preferably I8 is V or I

<400>  114

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5               


<210>  115
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  G1 is selected from the group consisting of V, S, R, D, G, A or 
       C, and analogs and isomers thereof, preferably G1 is G

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  E2 is selected from the group consisting of V, Q, K, D, E, G or 
       A, and analogs and isomers thereof, preferably E2 is K or E

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  A3 is selected from the group consisting of G, D, A, V, T, S or 
       P, and analogs and isomers thereof, preferably A3 is D

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  P4 is selected from the group consisting of T, P, Q, R, S, L or 
       A, and analogs and isomers thereof, preferably P4 is T or P

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  S5 is selected from the group consisting of Y, S, P, T, C, A or 
       F, and analogs and isomers thereof, preferably S5 is S

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  P6 is selected from the group consisting of T, R, S, Q, L, P or 
       A, and analogs and isomers thereof, preferably P6 is T, Q or P

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Y7 is selected from the group consisting of H, N, C, F, D, Y or 
       S, and analogs and isomers thereof, preferably Y7 is C

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  N8 is selected from the group consisting of N, K, H, I, D, Y, T 
       or S, and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  S9 is selected from the group consisting of T, S, P, A or L, and 
       analogs and isomers thereof, preferably S9 is S

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  R10 is selected from the group consisting of G, K, M, R, S, T or 
       W, and analogs and isomers thereof, preferably R10 is M

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  F11 is selected from the group consisting of C, F, I, L, S, V or 
       Y, and analogs and isomers thereof, preferably F11 is V

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  E12 is present or absent, and if present E12 is selected from the
       group consisting of Q, V, K, A, E, D or G, and analogs and 
       isomers thereof, preferably E12 is E

<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  S13 is present or absent, and if present S13 is selected from the
       group consisting of L, A, S, P, W or T, and analogs and isomers 
       thereof

<220>
<221>  MISC_FEATURE
<222>  (14)..(14)
<223>  V14 is present or absent, and if present V14 is selected from the
       group consisting of V, A, D, G, F, I or L, and analogs and 
       isomers thereof, preferably V14 is V

<220>
<221>  MISC_FEATURE
<222>  (15)..(15)
<223>  A15 is present or absent, and if present is selected from the 
       group consisting of S, P, V, T, A, G or D, and analogs and 
       isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  W16 is present or absent, and if present, is selected from the 
       group consisting of C, G, L, R or S, and analogs and isomers 
       thereof, preferably W16 is L

<400>  115

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10                  15      


<210>  116
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  F1 is selected from the group consisting of F, L, I, C, Y, V or 
       S, and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  S2 is selected from the group consisting of T, P, S, L or A, and 
       analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Y3 is selected from the group consisting of H, N, C, D, F, Y or 
       S, and analogs and isomers thereof, preferably Y3 is D

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  K4 is selected from the group consisting of M, N, K, E, T, R or 
       Q, and analogs and isomers thereof, preferably K4 is K or R

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Y5 is selected from the group consisting of S, Y, F, N, H, D or 
       C, and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  G6 is selected from the group consisting of G, R, S, D, A, C or 
       V, and analogs and isomers thereof, preferably G6 is D

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  N7 is selected from the group consisting of T, S, Y, D, N, K, H 
       or I, and analogs and isomers thereof, preferably N7 is D

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  G8 is selected from the group consisting of C, A, G, D, S, R or 
       V, and analogs and isomers thereof, preferably G8 is C or G

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  V9 is selected from the group consisting of D, G, V, I, L, A or 
       F, and analogs and isomers thereof, preferably V9 is G or F

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  W10 is selected from the group consisting of L, S, R, G or C, and
       analogs and isomers thereof, preferably W10 is L

<400>  116

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10  


<210>  117
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  C1 is selected from the group consisting of C, G, F, Y, S, R or 
       W, and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  M2 is selected from the group consisting of V, T, L, I, K or R, 
       and analogs and isomers thereof, preferably M2 is L

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  R3 is selected from the group consisting of W, T, M, K, R, G or 
       S, and analogs and isomers thereof, preferably R3 is R

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  P4 is selected from the group consisting of L, A, H, T, P, S or 
       R, and analogs and isomers thereof, preferably P4 is H or P

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  C5 is selected from the group consisting of S, G, F, C, W, R or 
       Y, and analogs and isomers thereof, preferably C5 is F

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  F6 is selected from the group consisting of V, S, Y, F, C, L or 
       I, and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  W7 is selected from the group consisting of L, S, R, G or C, and 
       analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  V8 is selected from the group consisting of D, L, F, A, I, G or 
       V, and analogs and isomers thereof, preferably V8 is V

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  E9 is selected from the group consisting of E, K, A, G, D, Q or 
       V, and analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  L10 is selected from the group consisting of V, S, L, I or F, and
       analogs and isomers thereof, preferably L10 is L

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  I11 is selected from the group consisting of S, T, N, I, L, F, V 
       or M, and analogs and isomers thereof, preferably I11 is V

<400>  117

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10      


<210>  118
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  K1 is selected from the group consisting of M, N, K, E, T, Q or 
       R, and analogs and isomers thereof, preferably K1 is M, N, K, T 
       or R

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  N2 is selected from the group consisting of T, Y, K, I, S, D, H 
       or N, and analogs and isomers thereof, preferably N2 is T, Y, K, 
       S or N

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  T3 is selected from the group consisting of I, N, A, S, P or T, 
       and analogs and isomers thereof, preferably T3 is I, N, A, S or T

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D4 is selected from the group consisting of V, H, N, Y, A, G, E 
       or D, and analogs and isomers thereof, preferably D4 is N, Y, A, 
       E or D

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  L5 is selected from the group consisting of P, R, V, F, I, L or 
       H, and analogs and isomers thereof, preferably L5 is I or L

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  E6 is selected from the group consisting of G, E, D, A, K, V or 
       Q, and analogs and isomers thereof, preferably E6 is E or D

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  V7 is selected from the group consisting of V, L, I, D, G, F or 
       A, and analogs and isomers thereof, preferably V7 is V, I, D, G 
       or A

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  L8 is selected from the group consisting of F, H, I, L, R, P or 
       V, and analogs and isomers thereof, preferably L8 is I or L

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  M9 is selected from the group consisting of R, V, T, K, I or L, 
       and analogs and isomers thereof, preferably M9 is R, V, K, I or L

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  E10 is selected from the group consisting of K, A, G, E, D, Q or 
       V, and analogs and isomers thereof, preferably E10 is E

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  W11 is selected from the group consisting of R, S, G, C or L, and
       analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  L12 is  selected from the group consisting of V, R, P, Q, L or I,
       and analogs and isomers thereof, preferably L12 is L or I

<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  K13 is selected from the group consisting of T, Q, R, M, N, K or 
       E, and analogs and isomers thereof, preferably K13 is N

<220>
<221>  MISC_FEATURE
<222>  (14)..(14)
<223>  T14 is selected from the group consisting of K, T, S, A, I, P or 
       R, and analogs and isomers thereof, preferably T14 is K, T or P

<220>
<221>  MISC_FEATURE
<222>  (15)..(15)
<223>  R15 is selected from the group consisting of S, R, T, I, K or G, 
       and analogs and isomers thereof, preferably R15 is R or I

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  P16 is selected from the group consisting of Q, P, S, R, T, L or 
       A, and analogs and isomers thereof, preferably P16 is Q or P

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  I17 is selected from the group consisting of T, V, S, F, M, L, N 
       or I, and analogs and isomers thereof, preferably I17 is I

<220>
<221>  MISC_FEATURE
<222>  (18)..(18)
<223>  L18 is selected from the group consisting of M, L, V, R, Q or P, 
       and analogs and isomers thereof, preferably L18 is L or V

<220>
<221>  MISC_FEATURE
<222>  (19)..(19)
<223>  S19 is selected from the group consisting of A, L, P, S or T, and
       analogs and isomers thereof

<220>
<221>  MISC_FEATURE
<222>  (20)..(20)
<223>  P20 is selected from the group consisting of T, P, S, R, A, L or 
       H, and analogs and isomers thereof, preferably P20 is T, P or H

<220>
<221>  MISC_FEATURE
<222>  (21)..(21)
<223>  L21 is selected from the group consisting of V, R, P, Q, L or M, 
       and analogs and isomers thereof, preferably L21 is V, L or M

<400>  118

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10                  15      


Xaa Xaa Xaa Xaa Xaa 
            20      


<210>  119
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide; CD4+ helper T cell epitope sequence

<400>  119

Ile Ser Gln Ala Val His Ala Ala His Ala Glu Ile Asn Glu Ala Gly 
1               5                   10                  15      


Arg 
    


<210>  120
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  120

Val Gln Asn Ala Leu Asn Gly Asn Gly Asp 
1               5                   10  


<210>  121
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  VARIANT
<222>  (1)..(1)
<223>  T or L

<220>
<221>  VARIANT
<222>  (3)..(3)
<223>  N or S

<220>
<221>  VARIANT
<222>  (6)..(6)
<223>  Q, H, or N

<220>
<221>  VARIANT
<222>  (7)..(7)
<223>  T or I

<220>
<221>  VARIANT
<222>  (8)..(8)
<223>  E or G

<220>
<221>  VARIANT
<222>  (9)..(9)
<223>  T or I

<400>  121

Xaa Gly Xaa Gln Asn Xaa Xaa Xaa Xaa Cys 
1               5                   10  


<210>  122
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  VARIANT
<222>  (1)..(1)
<223>  S or E

<220>
<221>  VARIANT
<222>  (9)..(9)
<223>  T or K

<220>
<221>  VARIANT
<222>  (10)..(10)
<223>  S or P

<400>  122

Xaa Ser Trp Ser Tyr Ile Val Glu Xaa Xaa 
1               5                   10  


<210>  123
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  VARIANT
<222>  (7)..(7)
<223>  T, S, or A

<220>
<221>  VARIANT
<222>  (8)..(8)
<223>  G or S

<220>
<221>  VARIANT
<222>  (9)..(9)
<223>  E, T, or I

<220>
<221>  VARIANT
<222>  (10)..(10)
<223>  I or V

<220>
<221>  VARIANT
<222>  (11)..(11)
<223>  T or M

<400>  123

Cys Ser Cys Tyr Pro Asp Xaa Xaa Xaa Xaa Xaa Cys Val Cys Arg Asp 
1               5                   10                  15      


Asn Trp His Gly Ser 
            20      


<210>  124
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  124

Leu Ser Asn Leu Ala Lys Gly Glu Lys Ala Asn Val Leu Ile Gly Gln 
1               5                   10                  15      


Gly Asp Val Val Leu Val Met Lys Arg Lys 
            20                  25      


<210>  125
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  VARIANT
<222>  (3)..(3)
<223>  L or I

<400>  125

Asp Thr Xaa Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Asp Thr Val 
1               5                   10                  15      


Asp Thr Val Leu Glu Lys Asn Val Thr Val 
            20                  25      


<210>  126
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  VARIANT
<222>  (3)..(3)
<223>  D or S

<400>  126

Leu Glu Xaa Val Phe Ala Gly Lys Asn Thr Asp Leu Glu Ala Leu Met 
1               5                   10                  15      


Glu Trp Leu Lys Thr 
            20      


<210>  127
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  127

Glu Gly Ser Tyr Phe Phe Gly Asp Asn Ala Glu 
1               5                   10      


<210>  128
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  128

Met Val Ala Tyr Met Leu Glu Arg Glu Leu Val Arg Lys 
1               5                   10              


<210>  129
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  129

Gly Glu Glu Met Ala Thr Lys Ala Asp Tyr 
1               5                   10  


<210>  130
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  130

Val Leu Ile Gly Gln Gly Asp Val Val Leu Val 
1               5                   10      


<210>  131
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  131

Tyr Met Leu Glu Arg Glu Leu Val 
1               5               


<210>  132
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  132

Tyr Met Leu Glu Arg Glu Leu Val Arg Lys 
1               5                   10  


<210>  133
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  133

Val Val Leu Val Met Lys Arg Lys 
1               5               


<210>  134
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  134

Ala Tyr Met Leu Glu Arg Glu Leu Val 
1               5                   


<210>  135
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  135

Gly Gln Gly Asp Val Val Leu Val Met 
1               5                   


<210>  136
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  136

Tyr His Ala Asn Asn Ser Thr Asp Thr Val 
1               5                   10  


<210>  137
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  137

Asn Leu Ala Lys Gly Glu Lys Ala Asn Val Leu 
1               5                   10      


<210>  138
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  138

Gly Glu Lys Ala Asn Val Leu Ile 
1               5               


<210>  139
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  139

Asn Thr Asp Leu Glu Val Leu Met 
1               5               


<210>  140
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  140

Leu Thr Asp Ser Gln Thr Ala Thr Lys 
1               5                   


<210>  141
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  141

Ser Thr Asp Thr Val Asp Thr Ile 
1               5               


<210>  142
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  142

Ile Leu Thr Asp Ser Gln Thr Ala 
1               5               


<210>  143
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  143

Val Leu Met Glu Trp Leu Lys Thr 
1               5               


<210>  144
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  144

Asp Thr Val Asp Thr Ile Leu Glu Lys Asn Val 
1               5                   10      


<210>  145
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  145

Val Gln Ile Ala Ser Asn Glu Asn Met 
1               5                   


<210>  146
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  146

Leu Glu Val Leu Met Glu Trp Leu 
1               5               


<210>  147
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  147

Lys Asn Thr Asp Leu Glu Val Leu Met Glu Trp 
1               5                   10      


<210>  148
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide; HLA DR-binding Epitope, PADRE

<400>  148

Ala Lys Phe Val Ala Ala Trp Thr Leu Lys Ala Ala Ala 
1               5                   10              


<210>  149
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide


<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  L-cyclohexylalanine

<220>
<221>  MISC_FEATURE
<222>  (14)..(14)
<223>  Aminocaproic acid

<400>  149

Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala Xaa Cys 
1               5                   10                  15  


